Lv41
500 积分 2024-11-21 加入
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
5天前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
27天前
已完结
The effects of incretins as a double-edged sword on cancer
28天前
已完结
Tirzepatide alters oncogenic signaling pathways in colorectal cancer cells in vitro
28天前
已关闭
941P Induction chemoimmunotherapy followed by radiotherapy and consolidation immunotherapy versus definitive concurrent chemoradiotherapy with consolidation immunotherapy for unresectable stage III non-small cell lung cancer: A single-center retrospective study
1个月前
已完结
Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study
1个月前
已完结
Camrelizumab plus chemotherapy in advanced non‐squamous non‐small cell lung cancer: Treatment response, survival pattern, and safety
1个月前
已完结
Acquired resistance in cancer: towards targeted therapeutic strategies
1个月前
已完结
Adjuvant therapy in stage IB non-small cell lung cancer: a network meta-analysis of tegafur-uracil and immune checkpoint inhibitors
1个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
